However, MT-2 has been studied primarily as a research compound, not as an FDA-approved obesity therapy, so long-term human data at standardized doses doesn't exist
The ubiquitous use of game changer in describing the benefits of the GLP-1 category of drugs is the latest example
This makes sense because the drugs work by modulating gut function
Robert Kushner: I haven't seen that paper, but what I can say which I thought you were getting to is that when we look at the categorical weight loss in all these trials, so some people lose 5%, 10%, 20%, 25% over the course of the trial, if you then stop the medication, the individuals who lost the greatest amount of body weight actually are the ones that regain it the quickest
[1] The synergistic effect of the blend may improve the overall flexibility and adjustability of the tissues following damage